ES2233940T3 - Induccion de tolerancia con proteinas de fusion tolerogenicas. - Google Patents

Induccion de tolerancia con proteinas de fusion tolerogenicas.

Info

Publication number
ES2233940T3
ES2233940T3 ES95910220T ES95910220T ES2233940T3 ES 2233940 T3 ES2233940 T3 ES 2233940T3 ES 95910220 T ES95910220 T ES 95910220T ES 95910220 T ES95910220 T ES 95910220T ES 2233940 T3 ES2233940 T3 ES 2233940T3
Authority
ES
Spain
Prior art keywords
epitope
immunoglobulin
fusion
cells
baselineskip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910220T
Other languages
English (en)
Spanish (es)
Inventor
David W. Scott
Elias T. Zambidis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American National Red Cross
Original Assignee
American National Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American National Red Cross filed Critical American National Red Cross
Application granted granted Critical
Publication of ES2233940T3 publication Critical patent/ES2233940T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fuses (AREA)
  • Burglar Alarm Systems (AREA)
  • Control Of High-Frequency Heating Circuits (AREA)
  • Lining Or Joining Of Plastics Or The Like (AREA)
ES95910220T 1994-02-14 1995-02-10 Induccion de tolerancia con proteinas de fusion tolerogenicas. Expired - Lifetime ES2233940T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US195874 1989-07-28
US08/195,874 US5817308A (en) 1994-02-14 1994-02-14 Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance

Publications (1)

Publication Number Publication Date
ES2233940T3 true ES2233940T3 (es) 2005-06-16

Family

ID=22723177

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910220T Expired - Lifetime ES2233940T3 (es) 1994-02-14 1995-02-10 Induccion de tolerancia con proteinas de fusion tolerogenicas.

Country Status (10)

Country Link
US (2) US5817308A (pt)
EP (1) EP0741788B1 (pt)
JP (2) JPH09509316A (pt)
AT (1) ATE288494T1 (pt)
CA (1) CA2182977A1 (pt)
DE (1) DE69533979T8 (pt)
DK (1) DK0741788T3 (pt)
ES (1) ES2233940T3 (pt)
PT (1) PT741788E (pt)
WO (1) WO1995021926A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
CA2315537A1 (en) 1997-12-16 1999-06-24 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
KR100518958B1 (ko) * 1998-05-20 2005-10-06 추가이 세이야쿠 가부시키가이샤 신규한 유전자 클로닝 방법
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
WO2001080880A2 (de) * 2000-04-22 2001-11-01 Stefan Barth Apoptotika
IL154284A0 (en) * 2000-09-25 2003-09-17 Nestle Sa Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2002085933A1 (en) * 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
US20120148585A1 (en) * 2001-05-01 2012-06-14 Andrew Saxon Fusion molecules and methods for treatment of immune diseases
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US8603471B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
CN101300355A (zh) * 2005-10-13 2008-11-05 威瑞克斯医药公司 包含丙型肝炎病毒多肽和用于引起免疫应答的Fc片段的嵌合抗原
EP2423222B2 (en) * 2007-01-30 2020-07-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
KR20150010716A (ko) 2012-03-23 2015-01-28 더 유니버시티 오브 퀸스랜드 면역조절제 및 이의 용도
CA2926221A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047244C (en) * 1989-02-24 2002-09-17 Zanetti Maurizio Genetically engineered immunoglobulins
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US5167956A (en) * 1991-02-11 1992-12-01 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in-vivo t cell suppressant activity
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance

Also Published As

Publication number Publication date
EP0741788A1 (en) 1996-11-13
DK0741788T3 (da) 2005-05-30
DE69533979T8 (de) 2006-11-09
PT741788E (pt) 2005-05-31
ATE288494T1 (de) 2005-02-15
JP2008001709A (ja) 2008-01-10
CA2182977A1 (en) 1995-08-17
DE69533979T2 (de) 2006-04-27
US20020048562A1 (en) 2002-04-25
JPH09509316A (ja) 1997-09-22
EP0741788B1 (en) 2005-02-02
US6838281B2 (en) 2005-01-04
DE69533979D1 (de) 2005-03-10
US5817308A (en) 1998-10-06
JP4214173B2 (ja) 2009-01-28
WO1995021926A1 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
ES2233940T3 (es) Induccion de tolerancia con proteinas de fusion tolerogenicas.
ES2305110T5 (es) Anticuerpos contra il-1 beta humana.
US5866129A (en) Method of producing an antibody with a peptide corresponding to membrane-bound IgA
ES2294793T3 (es) Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico.
ES2293748T3 (es) Moleculas de fijacion poliespecificas y usos de las mismas.
ES2144424T5 (es) Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.
JPH08505878A (ja) 免疫原のリソソーム標的
JPH05507197A (ja) 結合部位を含む可溶性ペプチド類縁体
US20060205016A1 (en) Protein a based binding domains with desirable activities
WO1992007574A1 (en) Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on b cells
JP2000515363A (ja) Ｍｈｃ複合体及びその用途
JP2001519143A (ja) 可溶性の一本鎖ｔ細胞レセプタータンパク質
KR100328112B1 (ko) 류마토이드관절염병원관련관절염성펩티드에대항하는면역보호유도에유용한백신조성물과방법
RU2763001C1 (ru) Однодоменное антитело и его модификации, специфически связывающиеся с RBD S белка вируса SARS-CoV-2, и способ их применения для терапии и экстренной профилактики заболеваний, вызываемых вирусом SARS-CoV-2
US5079344A (en) Antigenic epitopes present on membrane-bound but not secreted IgA
WO1993019178A2 (en) Peptides useful for inducing tolerance
JP3862752B2 (ja) 全身性エリテマトーデス治療用の合成ベプチドおよびこれを含有する薬剤組成物
Thomas et al. Nature of T lymphocyte recognition of macrophage-associated antigens. V. Contribution of individual peptide residues of human fibrinopeptide B to T lymphocyte responses.
ES2254663T3 (es) Peptidos capaces de enlazarse a cd64 y que comprenden uno o mas epitopos heterologos de celulas t, y sus usos.
US5362643A (en) Antibodies to epitopes present on membrane-bound but not secreted IGA
US5310875A (en) Peptides corresponding to membrane-bound IgA
Reitan et al. The primary IgM antibody repertoire: a source of potent idiotype immunogens
US5484907A (en) Nucleotides coding for the extracellular membrane-bound segment of IgA
Sela A peripatetic and personal view of molecular immunology for one third of the century
Mackewicz Molecular and cellular features governing T cell responsiveness to a defined protein antigen